A brief overview of iatrogenic akathisia

Clinical Schizophrenia and Related Psychoses

Volumn 3, Issue 4, 2010, Pages 226-236

  Advokat, Claire ^a  

^a LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

Akathisia; Psychopharmacology; Side Effects

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; ROPINIROLE; SEROTONIN 2 ANTAGONIST;

AKATHISIA; BIPOLAR DISORDER; DISTRESS SYNDROME; DOPAMINERGIC ACTIVITY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; HUMAN; PATHOPHYSIOLOGY; RESTLESSNESS; REVIEW; TREATMENT REFUSAL;

EID: 75749128259     PISSN: 19351232     EISSN: None     Source Type: Journal    
DOI: 10.3371/CSRP.3.4.5     Document Type: Review

References (83)

1. Adler LA, Angrist B, Reiter S, Rotrosen J. Neuroleptic-induced akathisia: a review. Psychopharmacol (Berl) 1989;97(1):1-11.
2. Sachdev P. The development of the concept of akathisia: a historical overview. Schizophr Res 1995;16(1):33-45.
3. Gibb WR, Lees AJ. The clinical phenomenon of akathisia. J Neurol Neurosurg Psychiatry 1986;49(8):861-866.
4. Mohr P, Volavka J. Ladislav Haskovec and akathisia: 100th anniversary. Br J Psychiatry 2002;181:537.
5. Kim JH, Byun HJ. Association of subjective cognitive dysfunction with akathisia in patients receiving stable doses of risperidone or haloperidol. J Clin Pharm Ther 2007;32(5):461-467.
6. Blaisdell GD. Akathisia: a comprehensive review and treatment summary. Pharmacopsychiatry 1994;27(4):139-146.
7. Bratti IM, Kane JM, Marder SR. Chronic restlessness with antipsychotics. Am J Psychiatry 2007;164(11):1648-1654.
8. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-676.
9. Fleischhacker WW, Bergmann KJ, Perovich R, Pestreich LK, Borenstein M, Lieberman JA, et al.. The Hillside Akathisia Scale: a new rating instrument for neuroleptic-induced akathisia. Psychopharmacol Bull 1989;25(2):222-226.
10. Van Putten T. The many faces of akathisia. Compr Psychiatry 1975;16(1):43-47.
11. Drake RE, Ehrlich J. Suicide attempts associated with akathisia. Am J Psychiatry 1985;142(4):499-501.
12. Raskin DE. Akathisia: a side effect to be remembered. Am J Psychiatry 1972;129(3):345-347.
13. Hirose S. Restlessness of respiration as a manifestation of akathisia: five case reports of respiratory akathisia. J Clin Psychiatry 2000;61(10):737-741.
14. Garcia MJ, Matson JL. Akathisia in adults with severe and profound intellectual disability: a psychometric study of the MEDS and ARMS. J Intellect Dev Disabil 2008;33(2):171-176.
15. Ratey JJ, Salzman C. Recognizing and managing akathisia. Hosp Community Psychiatry 1984;35(10):975-977.
16. Sachdev P, Kruk J. Clinical characteristics and predisposing factors in acute drug-induced akathisia. Arch Gen Psychiatry 1994;51(12):963-974.
17. Braude WM, Barnes TR, Gore SM. Clinical characteristics of akathisia: a systematic investigation of acute psychiatric inpatient admissions. Br J Psychiatry 1983;143:139-150.
18. Janno S, Holi M, Tuisku K, Wahlbeck K. Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients. Am J Psychiatry 2004;161(1):160-163.
19. Modestin J, Wehrli MV, Stephan PL, Agarwalla P. Evolution of neuroleptic-induced extrapyramidal syndromes under long-term neuroleptic treatment. Schizophr Res 2008;100(1-3):97-107.
20. Burke RE, Kang UJ, Jankovic J, Miller LG, Fahn S. Tardive akathisia: an analysis of clinical features and response to open therapeutic trials. Mov Disord 1989;4(2):157-175.
21. Miller CH, Fleischhacker WW. Managing antipsychotic-induced acute and chronic akathisia. Drug Saf 2000;22(1):73-81.
22. Munetz MR, Cornes CL. Distinguishing akathisia and tardive dyskinesia: a review of the literature. J Clin Psychopharmacol 1983;3(6):343-350.
23. Catalano G, Grace JW, Catalano MC, Morales MJ, Cruse LM. Acute akathisia associated with quetiapine use. Psychosomatics 2005;46(4):291-301.
24. Bhattacharjee J, Ei-Sayeh HG. Aripiprazole versus typicals for schizophrenia. Cochrane Database Syst Rev 2008 Jul 16;(3):CD006617. DOI: 10.1002/14651858. CD006617.pub2.
25. Haddad PM, Dursun SM. Neurological complications of psychiatric drugs: clinical features and management. Hum Psychopharmacol 2008;23 Suppl 1:15-26.
26. Markkula J, Helenius H, Lauerma H. On the relationship of atypical and low-dose conventional antipsychotics with akathisia in a clinical patient population. Nordic J Psychiatry 2007;61(2):152-157.
27. Miller CH, Mohr F, Umbricht D, Woerner M, Fleischhacker WW, Lieberman JA. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. J Clin Psychiatry 1998;59(2):69-75.
28. Cohen BM, Keck PE, Satlin A, Cole JO. Prevalence and severity of akathisia in patients on clozapine. Biol Psychiatry 1991;29(12):1215-1219.
29. Meltzer HY, Bobo WV, Nuamah IF, Lane R, Hough D, Kramer M, et al.. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatry 2008;69(5):817-829.
30. Bharadwaj R, Grover S. Parkinsonism and akathisia with quetiapine: three case reports. J Clin Psychiatry 2008;69(7):1189-1191.
31. Cortese L, Caligiuri MP, Williams R, Schieldrop P, Manchanda R, Malla A, et al.. Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia. J Clin Psychopharmacol 2008;28(1):69-73.
32. Levine J, Chengappa KN. Second thoughts about clozapine as a treatment for neuroleptic-induced akathisia. J Clin Psychiatry 1998;59(4):195.
33. Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol 2008;28(2 Suppl 1):S20-S28.
34. Kane JM, Lauriello J, Laska E, Di Marino M, Wolfgang CD. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. J Clin Psychopharmacol 2008;28(2 Suppl 1):S29-S35.
35. Weiden PJ, Cutler AJ, Polymeropoulos MH, Wolfgang CD. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials. J Clin Psychopharmacol 2008;28(2 Suppl 1):S12-S19.
36. Padder T, Skodnek K, Hashmi S, Samad M, Udyawar A, Azhar N, et al.. Acute akathisia with suicidal ideation associated with low dose aripiprazole. Psychiatry 2006;3(4):40-43.
37. Hettema JM, Ross DE. A case of aripiprazole-related tardive akathisia and its treatment with ropinirole. J Clin Psychiatry 2007;68(11):1814-1815.
38. Kemp DE, Gilmer WS, Fleck J, Straus JL, Dago PL, Karaffa M. Aripiprazole augmentation in treatment-resistant bipolar depression: early response and development of akathisia. Prog Neuropsychopharmacol Biol Psychiatry 2007;31(2):574-577. (Pubitemid 46209454)
39. Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, et al.. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008;28(2):156-165.
40. Poyurovsky M, Weizman R, Weizman A. Aripiprazole's receptor pharmacology and extrapyramidal side effects. Am J Psychiatry 2008;165(3):398.
41. Iqbal N, Lambert T, Masand P. Akathisia: problem of history or concern of today. CNS Spectr 2007;12(9 Suppl 14):1-13.
42. Lane RM. SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment. J Psychopharmacol 1998;12(2):192-214.
43. Gill HS, DeVane CL, Risch SC. Extrapyramidal symptoms associated with cyclic antidepressant treatment: a review of the literature and consolidating hypotheses. J Clin Psychopharmacol 1997;17(5):377-389.
44. Hullett FJ, Levy AB. Amoxapine-induced akathisia. Am J Psychiatry 1983;149(6):820.
45. Eberstein S, Adler LA, Angrist B. Nefazodone and akathisia. Biol Psychiatry 1996;40(8):798-799.
46. Girishchandra BG, Johnson L, Cresp RM, Orr KG. Mirtazepine-induced akathisia. Med J Aust 2002;176(5):242.
47. Leo RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 1996;57(10):449-454.
48. Lipinski JF Jr, Mallya G, Zimmerman MG, Pope HG Jr. Fluoxetine-induced akathisia: clinical and theoretical implications. J Clin Psychiatry 1989;50(9):339-342.
49. Zubenko GS, Barreira P, Lipinski JF Jr. Development of tolerance to the therapeutic effect of amantadine on akathisia. J Clin Psychopharmacol 1984;4(4):218-220.
50. Chong SA, Tan CH. Fluvoxamine and akathisia. J Clin Psychopharmacol 1996;16(4):334-335.
51. Baldassano CF, Truman CJ, Nierenberg A, Ghaemi SN, Sachs GS. Akathisia: a review and case report following paroxetine treatment. Compr Psychiatry 1996;37(2):122-124.
52. Bauer M, Hellweg R, Baumgartner A. Fluoxetine-induced akathisia does not reappear after switch to paroxetine. J Clin Psychiatry 1996;57(12):593-594.
53. Gao K, Kemp DE, Ganocy SJ, Gajwani P, Xia G, Calabrese JR. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol 2008;28(2):203-209.
54. Rothschild AJ, Locke CA. Reexposure to fluoxetine after serious suicide attempts by three patients: the role of akathisia. J Clin Psychiatry 1991;52(12):491-493.
55. Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord 2007;22(2):193-197. (Pubitemid 46374760)
56. Back I, Taubert M. Akathisia and an unusual symptomatic treatment: a case report. Palliat Med 2007;21(8):713-715.
57. Wright MT. Antiemetics, akathisia, and pregnancy. Psychosomatics 2007;48(6):461-466.
58. Sekine Y, Rikihisa T, Ogata H, Echizen H, Arakawa Y. Correlations between in vitro affinity of antipsychotics to various central neurotransmitter receptors and clinical incidence of their adverse drug reactions. Eur J Clin Pharmacol 1999;55(8):583-587.
59. Lipinski JF Jr, Zubenko GS, Cohen BM, Barreira PJ. Propranolol in the treatment of neuroleptic-induced akathisia. Am J Psychiatry 1984;141(3):412-415.
60. Rathbone J, Soares-Weiser K. Anticholinergics for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev 2006 Oct 18;(4):CD003727. DOI: 10.1002/14651858. CD003727.pub3.
61. Baskak B, Atbasoglu EC, Ozguven HD, Saka MC, Gogus AK. The effectiveness of intramuscular biperiden in acute akathisia: a double-blind, randomized, placebo- controlled study. J Clin Psychopharmacol 2007:27(3):289-294.
62. Parlak I, Erdur B, Parlak M, Ergin A, Ayrik C, Tomruk O, et al.. Midazolam vs. diphenhydramine for the treatment of metoclopramide-induced akathisia: a randomized controlled trial. Acad Emerg Med 2007;14(8):714-721.
63. Comaty JE. Propranolol treatment of neuroleptic-induced akathisia. Psychiatr Ann 1987;17:150-153.
64. Kulik AV, Wilbur R. Case report of propranolol (Inderal) pharmacotherapy for neuroleptic-induced akathisia and tremor. Prog Neuropsychopharmacol Biol Psychiatry 1983;7(2-3):223-225.
65. Goyal R, Chandrasekaran R, Nanda MR. Propranolol-responsive akathisia following acute encephalitis. Gen Hosp Psychiatry 2007;29(3):273-274.
66. Dumon JP, Catteau J, Lanvin F, Dupuis BA. Randomized, double-blind, crossover, placebo-controlled comparison of propranolol and betaxolol in the treatment of neuroleptic-induced akathisia. Am J Psychiatry 1992;149(5):647-650.
67. Poyurovsky M, Fuchs C, Weizman A. Low-dose mianserin in treatment of acute neuroleptic-induced akathisia. J Clin Psychopharmacol 1998;18(3):253-254.
68. Poyurovsky M, Shardorodsky M, Fuchs C, Schneidman M, Weizman A. Treatment of neuroleptic-induced akathisia with the 5-HT2 antagonist mianserin. Double-blind, placebo-controlled study. Br J Psychiatry 1999;174:238-242.
69. Fischel T, Hermesh H, Aizenberg D, Zemishlany Z, Munitz H, Benjamini Y, et al.. Cyproheptadine versus propranolol for the treatment of acute neuroleptic-induced akathisia: a comparative double-blind study. J Clin Psychopharmacol 2001;21(6):612-615.
70. Poyurovsky M, Weizman A. Mirtazepine for neuroleptic-induced akathisia. Am J Psychiatry 2001;158(5):819.
71. Wilson MS 2nd. Mirtazepine for akathisia in bipolar disorder. J Clin Psychopharmacol 2005;25(4):394-395.
72. Hieber R, Dellenbaugh T, Nelson LA. Role of mirtazapine in the treatment of antipsychotic-induced akathisia. Ann Pharmacother 2008;42(6):841-846.
73. Poyurovsky M, Weizman A. Serotonin-based pharmacotherapy for acute neuroleptic-induced akathisia: a new approach to an old problem. Br J Psychiatry 2001;179:4-8.
74. Chelben J, Strous RD, Lustig M, Baruch Y. Remission of SSRI-induced akathisia after switch to nefazodone. J Clin Psychiatry 2001;62(7):570-571.
75. Fehr C, Dahmen N, Klawe C, Eicke M, Szegedi A. Piracetam in the treatment of tardive dyskinesia and akathisia: a case report. J Clin Psychopharmacol 2001;21(2):248-249.
76. Sivrioglu EY, Kirli S, Sipahioglu D, Gursoy B, Sarandol E. The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an open-label pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2007;31(7):1493-1499.
77. Anfang MK, Pope HG Jr. Treatment of neuroleptic-induced akathisia with nicotine patches. Psychopharmacol (Berl) 1997;134(2):153-156.
78. De Leon J, Diaz FJ, Aguilar MC, Jurado D, Gurpegui M. Does smoking reduce akathisia? Testing a narrow version of the self-medication hypothesis. Schizophr Res 2006;86(1-3):256-268.
79. Akagi H, Kumar TM. Lesson of the week: Akathisia: overlooked at a cost. BMJ 2002;324(7352):1506-1507.
80. Voruganti LN, Awad AG. Subjective and behavioural consequences of striatal dopamine depletion in schizophrenia-findings from an in vivo SPECT study. Schizophr Res 2006;88(1-3):179-186.
81. Loonen AJ, Van Praag HM. Measuring movement disorders in antipsychotic drug trials: the need to define a new standard. J Clin Psychopharmacol 2007;27(5):423-430.
82. Janno S, Holi MM, Tuisku K, Wahlbeck K. Neuroleptic-induced movement disorders in a naturalistic schizophrenia population: diagnostic value of actometric movement patterns. BMC Neurol 2008;8:10. DOI: 10.1186/1471-2377-8-10. (Pubitemid 351659539)
83. Hansen LK. Akathisia-seen from the patients' perspective. J Psychopharmacol 2008;22(5):572-573.